Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 100,117 Shares of Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 100,117 shares of Alamar Biosciences stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $29.38, for a total value of $2,941,437.46. Following the completion of the sale, the insider directly owned 157,217 shares in the company, valued at $4,619,035.46. This trade represents a 38.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Tuesday, November 3rd, Corporate Gp Vi Ltd. Qiming sold 111,313 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.89, for a total value of $3,327,145.57.
• On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.84, for a total value of $1,310,871.20.
• On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.38, for a total value of $4,365,788.28.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total value of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total value of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total value of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total transaction of $3,960,491.56.

Alamar Biosciences Trading Down 3.0%

Shares of ALMR stock traded down $0.95 on Friday, reaching $30.81. The company’s stock had a trading volume of 667,712 shares, compared to its average volume of 745,923. The stock’s fifty day simple moving average is $30.25 and its 200-day simple moving average is $27.16. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $39.61. The company has a market capitalization of $2.14 billion and a price-to-earnings ratio of -14.33.

Alamar Biosciences (NASDAQ:ALMR) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. Alamar Biosciences had a negative net margin of 48.22% and a negative return on equity of 78.71%. Equities research analysts forecast that Alamar Biosciences, Inc. will post -1.29 earnings per share for the current year.

Institutional Trading of Alamar Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ALMR. China Universal Asset Management Co. Ltd. purchased a new stake in Alamar Biosciences during the 3rd quarter valued at $196,000. Squarepoint Ops LLC bought a new position in Alamar Biosciences during the second quarter valued at $283,000. Palumbo Wealth Management LLC increased its position in Alamar Biosciences by 16.5% during the third quarter. Palumbo Wealth Management LLC now owns 16,934 shares of the company’s stock valued at $577,000 after acquiring an additional 2,402 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Alamar Biosciences in the third quarter valued at $606,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Alamar Biosciences by 18.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Stifel Nicolaus boosted their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. upped their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Alamar Biosciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, November 4th. Finally, TD Cowen lifted their price target on Alamar Biosciences from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.00.

About Alamar Biosciences

Alamar Biosciences is a life sciences tools company that develops technologies for measuring proteins in biological samples. Its products are designed to help researchers study disease biology and support the development of tools for earlier disease detection and precision medicine. The company’s offerings include its NULISA platform, which enables sensitive measurement of multiple proteins, and the ARGO HT system, an automated instrument for running assays. Its applications include research into neurodegenerative diseases, cancer and inflammation.